Actelion Ltd. is a leading biopharmaceutical company focused on the discovery,development and commercialization of innovative drugs for diseases with significant unmet medical needs. The company has its corporate headquarters in Allschwil/Basel, Switzerland where it was founded in 1997. Its shares have been listed on the SIX Swiss Exchange (ticker symbol ALTN) since 2000. In September 2008, Actelion shares began trading as part of the blue-chip SMI® (Swiss Market Index).
The company has proven its ability to discover new compounds and to rapidly move them from research through development to commercialization. In particular, Actelion scientists were among the first to work in the field of endothelin receptor antagonists (ERA), leading to Tracleer® and now the tailored ERA Opsumit®.
Actelion has over 30 operative affiliates around the world including the United States, Canada, Brazil,
Australia, Japan, Switzerland and a number of EU countries. These subsidiaries provide distribution,
sales and marketing services.